Nonoperating Income (Expense) of OptimizeRx Corp from 31 Dec 2013 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
OptimizeRx Corp quarterly and annual Nonoperating Income (Expense) in USD history and change rate from 31 Dec 2013 to 31 Dec 2025.
  • OptimizeRx Corp Nonoperating Income (Expense) for the quarter ending 31 Dec 2025 was $1,096,000, a 23% increase year-over-year.
  • OptimizeRx Corp Nonoperating Income (Expense) for the twelve months ending 31 Dec 2025 was $4,743,000, a 16% increase year-over-year.
  • OptimizeRx Corp annual Nonoperating Income (Expense) for 2025 was $4,743,000, a 16% increase from 2024.
  • OptimizeRx Corp annual Nonoperating Income (Expense) for 2024 was $5,679,000, a 559% decline from 2023.
  • OptimizeRx Corp annual Nonoperating Income (Expense) for 2023 was $1,238,000, a 45% increase from 2022.
Source SEC data
View on sec.gov
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Change (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Change (%)

OptimizeRx Corp Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $4,743,000 $1,096,000 +$331,000 +23% 01 Oct 2025 31 Dec 2025 10-K 12 Mar 2026 2025 FY
Q3 2025 $5,074,000 $1,001,000 +$378,000 +27% 01 Jul 2025 30 Sep 2025 10-Q 07 Nov 2025 2025 Q3
Q2 2025 $5,452,000 $1,476,000 -$129,000 -9.6% 01 Apr 2025 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $5,323,000 $1,170,000 +$356,000 +23% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $5,679,000 $1,427,000 -$591,000 -71% 01 Oct 2024 31 Dec 2024 10-K 12 Mar 2026 2025 FY
Q3 2024 $5,088,000 $1,379,000 -$2,067,000 -300% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2025 2025 Q3
Q2 2024 $3,021,000 $1,347,000 -$2,068,000 -287% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2025 2025 Q2
Q1 2024 $953,000 $1,526,000 -$2,191,000 -329% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $1,238,000 $836,000 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
Q3 2023 $688,000 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $721,000 01 Apr 2023 30 Jun 2023 10-Q 15 Aug 2024 2024 Q2
Q1 2023 $665,000 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q3 2019 $232,839 $416,368 +$394,618 +1814% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2019 2019 Q3
Q2 2019 $161,779 $73,426 -$80,338 -1162% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2019 2019 Q2
Q1 2019 $81,441 $125,636 -$127,653 -6329% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2019 2019 Q1
Q4 2018 $46,212 $15,533 +$13,287 +592% 01 Oct 2018 31 Dec 2018 10-K 12 Mar 2019 2018 FY
Q3 2018 $32,925 $21,750 +$14,878 +217% 01 Jul 2018 30 Sep 2018 10-Q 05 Nov 2019 2019 Q3
Q2 2018 $18,047 $6,912 -$2,151 -24% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2
Q1 2018 $20,198 $2,017 -$5,739 -74% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $25,937 $2,246 -$12,934 -85% 01 Oct 2017 31 Dec 2017 10-K 12 Mar 2019 2018 FY
Q3 2017 $38,871 $6,872 +$238 +3.6% 01 Jul 2017 30 Sep 2017 10-Q 05 Nov 2018 2018 Q3
Q2 2017 $38,633 $9,063 -$1,519 -14% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $40,152 $7,756 -$2,157 -22% 01 Jan 2017 31 Mar 2017 10-Q 02 May 2018 2018 Q1
Q4 2016 $42,309 $15,180 +$13,881 +1069% 01 Oct 2016 31 Dec 2016 10-K 08 Mar 2018 2017 FY
Q3 2016 $28,428 $6,634 +$6,266 +1703% 01 Jul 2016 30 Sep 2016 10-Q 02 Nov 2017 2017 Q3
Q2 2016 $22,162 $10,582 +$10,278 +3381% 01 Apr 2016 30 Jun 2016 10-Q 01 Aug 2017 2017 Q2
Q1 2016 $11,884 $9,913 +$9,617 +3249% 01 Jan 2016 31 Mar 2016 10-Q 03 May 2017 2017 Q1
Q4 2015 $2,267 $1,299 +$996 +329% 01 Oct 2015 31 Dec 2015 10-K 08 Mar 2017 2016 FY
Q3 2015 $1,271 $368 +$65 +21% 01 Jul 2015 30 Sep 2015 10-Q 07 Nov 2016 2016 Q3
Q2 2015 $1,206 $304 +$81 +36% 01 Apr 2015 30 Jun 2015 10-Q 08 Aug 2016 2016 Q2
Q1 2015 $1,125 $296 +$190 +179% 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016 2016 Q1
Q4 2014 $935 $303 01 Oct 2014 31 Dec 2014 10-K 15 Mar 2016 2015 FY
Q3 2014 $303 01 Jul 2014 30 Sep 2014 10-Q 12 Nov 2015 2015 Q3
Q2 2014 $223 01 Apr 2014 30 Jun 2014 10-Q 11 Aug 2015 2015 Q2
Q1 2014 $106 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015 2015 Q1

OptimizeRx Corp Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $4,743,000 +$936,000 +16% 01 Jan 2025 31 Dec 2025 10-K 12 Mar 2026 2025 FY
2024 $5,679,000 -$6,917,000 -559% 01 Jan 2024 31 Dec 2024 10-K 12 Mar 2026 2025 FY
2023 $1,238,000 +$385,702 +45% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
2022 $852,298 01 Jan 2022 31 Dec 2022 10-K 15 Apr 2024 2023 FY
2018 $46,212 +$20,275 +78% 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2019 2018 FY
2017 $25,937 -$16,372 -39% 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2019 2018 FY
2016 $42,309 +$40,042 +1766% 01 Jan 2016 31 Dec 2016 10-K 08 Mar 2018 2017 FY
2015 $2,267 +$1,332 +142% 01 Jan 2015 31 Dec 2015 10-K 08 Mar 2017 2016 FY
2014 $935 +$689 +280% 01 Jan 2014 31 Dec 2014 10-K 15 Mar 2016 2015 FY
2013 $246 01 Jan 2013 31 Dec 2013 10-K 16 Sep 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.